ketoconazole has been researched along with Long QT Syndrome in 15 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
Long QT Syndrome: A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levoketoconazole is a ketoconazole stereoisomer in development for treatment of Cushing's syndrome and has not been assessed previously in a clinical trial in patients with Cushing's syndrome." | 9.30 | Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. ( Auchus, RJ; Biller, BMK; Cohen, F; Elenkova, A; Feelders, RA; Fleseriu, M; Geer, EB; Greenman, Y; Pivonello, R; Salvatori, R; Witek, P, 2019) |
| "Levoketoconazole is a ketoconazole stereoisomer in development for treatment of Cushing's syndrome and has not been assessed previously in a clinical trial in patients with Cushing's syndrome." | 5.30 | Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. ( Auchus, RJ; Biller, BMK; Cohen, F; Elenkova, A; Feelders, RA; Fleseriu, M; Geer, EB; Greenman, Y; Pivonello, R; Salvatori, R; Witek, P, 2019) |
| "To assess the steady-state pharmacokinetic and QT(c) effects of domperidone and ketoconazole, given alone and together." | 2.77 | Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study. ( Baisley, KJ; Boyce, MJ; Warrington, SJ, 2012) |
| "The present clinical trial was designed to evaluate the possible pharmacokinetic and electrocardiographic interactions of the gastroenteric prokinetic drug cinitapride with ketoconazole." | 2.73 | The prokinetic cinitapride has no clinically relevant pharmacokinetic interaction and effect on QT during coadministration with ketoconazole. ( Esbri, R; Golor, G; Pavesi, M; Robert, M; Roberts, D; Salvà, M; Segarra, R, 2007) |
| " The aim of this study was to assess the QT interval in patients with Cushing's disease during long-term administration of ketoconazole." | 1.43 | No Untoward Effect of Long-Term Ketoconazole Administration on Electrocardiographic QT Interval in Patients with Cushing's Disease. ( Cavagnini, F; De Martin, M; Goulene, K; Pecori Giraldi, F; Radaelli, P; Stramba-Badiale, M; Toja, PM, 2016) |
| "Latent tuberculosis infection is an important problem for solid organ transplant recipients because of the frequency of its occurrence and its potential for reactivation." | 1.39 | Use of rifabutin for the treatment of a latent tuberculosis infection in a patient after solid organ transplantation. ( Chin-Hong, PV; Hickey, MD; Quan, DJ; Roberts, JP, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 9 (60.00) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fleseriu, M | 1 |
| Pivonello, R | 1 |
| Elenkova, A | 1 |
| Salvatori, R | 1 |
| Auchus, RJ | 1 |
| Feelders, RA | 1 |
| Geer, EB | 1 |
| Greenman, Y | 1 |
| Witek, P | 1 |
| Cohen, F | 1 |
| Biller, BMK | 1 |
| Hickey, MD | 1 |
| Quan, DJ | 1 |
| Chin-Hong, PV | 1 |
| Roberts, JP | 1 |
| De Martin, M | 1 |
| Toja, PM | 1 |
| Goulene, K | 1 |
| Radaelli, P | 1 |
| Cavagnini, F | 1 |
| Stramba-Badiale, M | 1 |
| Pecori Giraldi, F | 1 |
| Yeung, KS | 1 |
| Meanwell, NA | 1 |
| Boyce, MJ | 1 |
| Baisley, KJ | 1 |
| Warrington, SJ | 1 |
| Potkin, SG | 1 |
| Preskorn, S | 1 |
| Hochfeld, M | 1 |
| Meng, X | 1 |
| Hamlin, RL | 1 |
| Kijtawornrat, A | 1 |
| Keene, BW | 1 |
| Hamlin, DM | 1 |
| Mok, NS | 1 |
| Lo, YK | 1 |
| Tsui, PT | 1 |
| Lam, CW | 1 |
| Darpo, B | 1 |
| Agin, M | 1 |
| Kazierad, DJ | 1 |
| Layton, G | 1 |
| Muirhead, G | 1 |
| Gray, P | 1 |
| Jorkasky, DK | 1 |
| Dumaine, R | 1 |
| Antzelevitch, C | 1 |
| Robert, M | 1 |
| Salvà, M | 1 |
| Segarra, R | 1 |
| Pavesi, M | 1 |
| Esbri, R | 1 |
| Roberts, D | 1 |
| Golor, G | 1 |
| Sarapa, N | 1 |
| Nickens, DJ | 1 |
| Raber, SR | 1 |
| Reynolds, RR | 1 |
| Amantea, MA | 1 |
| Takemasa, H | 1 |
| Nagatomo, T | 1 |
| Abe, H | 1 |
| Kawakami, K | 1 |
| Igarashi, T | 1 |
| Tsurugi, T | 1 |
| Kabashima, N | 1 |
| Tamura, M | 1 |
| Okazaki, M | 1 |
| Delisle, BP | 1 |
| January, CT | 1 |
| Otsuji, Y | 1 |
| Zimmermann, M | 1 |
| Duruz, H | 1 |
| Guinand, O | 1 |
| Broccard, O | 1 |
| Levy, P | 1 |
| Lacatis, D | 1 |
| Bloch, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome[NCT01838551] | Phase 3 | 94 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The response to COR-003 is defined as mean UFC concentration ≤ULN following 6 months of maintenance phase therapy without a prior dose increase during that phase. The proportion of responders at the End of Maintenance Phase visit, following 6 months of treatment in the Maintenance Phase, for all dose groups combined was estimated using a generalized linear model with repeated measurements based on a binomial distribution with a logit link function and with region (US vs. non-US), concurrent CS medical conditions (diabetes [Yes/No], hypertension [Yes/No]), age (rounded median split based on the ITT population), sex, disease duration (years), prior CS medication (Yes/No), prior radiation therapy (Yes/No) as Baseline covariates and visit as an independent factor.~The least squares mean (LSMEAN) estimate of the UFC response after 6 months of treatment in the Maintenance Phase alongside its 95% Wald CI is presented." (NCT01838551)
Timeframe: 6 months of maintenance phase therapy without a prior dose increase during that phase
| Intervention | proportion of subjects meeting endpoint (Least Squares Mean) |
|---|---|
| Levoketoconazole All Doses | .30 |
6 trials available for ketoconazole and Long QT Syndrome
| Article | Year |
|---|---|
Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial.
Topics: Adolescent; Adrenal Insufficiency; Adult; Aged; Alanine Transaminase; Chemical and Drug Induced Live | 2019 |
Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study.
Topics: 14-alpha Demethylase Inhibitors; Adolescent; Adult; Analysis of Variance; Area Under Curve; Arrhythm | 2012 |
A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhi | 2013 |
Man versus machine: is there an optimal method for QT measurements in thorough QT studies?
Topics: Adolescent; Adult; Aza Compounds; Control Groups; Cross-Over Studies; Electrocardiography; Female; F | 2006 |
The prokinetic cinitapride has no clinically relevant pharmacokinetic interaction and effect on QT during coadministration with ketoconazole.
Topics: Administration, Oral; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzamides; Biological | 2007 |
Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies.
Topics: Adult; Aza Compounds; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors | 2008 |
9 other studies available for ketoconazole and Long QT Syndrome
| Article | Year |
|---|---|
Use of rifabutin for the treatment of a latent tuberculosis infection in a patient after solid organ transplantation.
Topics: Adolescent; Antibiotics, Antitubercular; Drug Interactions; Drug Monitoring; Drug Substitution; Drug | 2013 |
No Untoward Effect of Long-Term Ketoconazole Administration on Electrocardiographic QT Interval in Patients with Cushing's Disease.
Topics: Adrenocorticotropic Hormone; Adult; Dose-Response Relationship, Drug; Electrocardiography; Female; H | 2016 |
Inhibition of hERG channel trafficking: an under-explored mechanism for drug-induced QT prolongation.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoxetine; Humans; Inhibitory Concentrati | 2008 |
QT and RR intervals in conscious and anesthetized guinea pigs with highly varying RR intervals and given QTc-lengthening test articles.
Topics: Anesthesia; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cisapride; Consciousness; Electro | 2003 |
Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug.
Topics: Antifungal Agents; Coronary Artery Disease; Female; Humans; Ketoconazole; Long QT Syndrome; Middle A | 2005 |
Disopyramide: although potentially life-threatening in the setting of long QT, could it be life-saving in short QT syndrome?
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Disopyramide; Drug Interaction | 2006 |
Interaction between ketoconazole and domperidone and the risk of QT prolongation--important safety information.
Topics: Antiemetics; Antifungal Agents; Domperidone; Drug Interactions; Humans; Ketoconazole; Long QT Syndro | 2006 |
Coexistence of hERG current block and disruption of protein trafficking in ketoconazole-induced long QT syndrome.
Topics: Antifungal Agents; Binding Sites; Blotting, Western; Cell Line; Dose-Response Relationship, Drug; El | 2008 |
Torsades de Pointes after treatment with terfenadine and ketoconazole.
Topics: Adult; Cardiac Pacing, Artificial; Dermatomycoses; Drug Therapy, Combination; Electrocardiography, A | 1992 |